Home » Topics » BioWorld Science

BioWorld Science
RSS

S100-B found to be a peripheral biomarker for estimating addiction treatment efficacy

Sep. 12, 2019

ANKRD12 as a novel biomarker in schizophrenia and bipolar disorder

Sep. 12, 2019

Positive CTC data from phase II TYME-88-PANC study of SM-88

Sep. 12, 2019

Tiziana presents phase I results for nasal foralumab

Sep. 12, 2019

Molecular Partners initiates first-in-human study of MP-0310

Sep. 12, 2019

Murine model reveals TRPA1 loss is involved in age-related dilated cardiomyopathy

Sep. 12, 2019

Pfizer reports preliminary data from phase II pediatric study of 20vPnC candidate

Sep. 10, 2019

Translate Bio discontinues MRT-5201 for OTC deficiency, prioritizes pulmonary disease programs

Sep. 10, 2019

Alector begins phase II study of AL-001 for frontotemporal dementia

Sep. 10, 2019

Prometic initiates phase I study of PBI-4547

Sep. 10, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...